Back to top
more

Pieris Pharmaceuticals (PIRS)

(Delayed Data from NSDQ)

$10.48 USD

10.48
1,902

-0.01 (-0.10%)

Updated May 24, 2024 03:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PIRS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Pieris Pharmaceuticals, Inc. [PIRS]

Reports for Purchase

Showing records 41 - 60 ( 91 total )

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 41

02/09/2018

Company Report

Pages: 6

Can These Guys Partner or What? Third Deal in 13 Months Signed

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 42

02/07/2018

Company Report

Pages: 10

Spotlight on Two Lead Assets at First KOL Event

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 43

01/16/2018

Company Report

Pages: 10

Driving Toward an Important Boost in Anticalin Visibility This Year; Target Increased to $12

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 44

12/20/2017

Daily Note

Pages: 5

PRS-060 Goes Clinical and Pieris Cashes a Check

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 45

11/10/2017

Company Report

Pages: 6

3Q17 Results; Moving Forward on Many Fronts; Clinical Data Should Start Rolling In

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 46

10/18/2017

Company Report

Pages: 6

Charting New Territory With First Anticalin Multi-Dose Study; Phase 2a Underway

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 47

08/11/2017

Company Report

Pages: 6

2Q17 Results; Building Activity Across Programs and Partnerships; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 48

06/05/2017

Company Report

Pages: 9

PRS-080 Phase 1b Data in CKD Patients Highlights Potential of the Novel Anticalins; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 49

06/05/2017

Company Report

Pages: 9

PRS-080 Phase 1b Data in CKD Patients Highlights Potential of the Novel Anticalins; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 50

05/30/2017

Company Report

Pages: 26

Anticalins for All; What Do You Want to Target? Initiating Coverage at Buy and $9 PT

Provider: Rodman & Renshaw, Co.

Price: 75.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 51

05/30/2017

Company Report

Pages: 26

Anticalins for All; What Do You Want to Target? Initiating Coverage at Buy and $9 PT

Provider: H.C. Wainwright & Co., Inc.

Price: 75.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 52

05/24/2017

Daily Note

Pages: 3

Corrected - Coverage Update - Healthcare

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 53

05/24/2017

Company Report

Pages: 4

We are transferring coverage due to the departure of the covering analyst

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 54

05/24/2017

Daily Note

Pages: 3

Coverage Update - Healthcare

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 55

04/06/2017

Industry Report

Pages: 13

Healthcare - Cancer in Washington: 2017 AACR Highlights

Provider: Roth Capital Partners, Inc.

Analyst: BREIDENBACH M

Price: 50.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 56

04/06/2017

Industry Report

Pages: 13

Healthcare - Cancer in Washington: 2017 AACR Highlights

Provider: Roth Capital Partners, Inc.

Analyst: BREIDENBACH M

Price: 50.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 57

12/19/2016

Company Report

Pages: 4

We are transferring coverage to Mark Breidenbach, Ph.D., due to the departure of the covering analyst and placing shares Under Review.

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 58

11/21/2016

Industry Report

Pages: 6

Healthcare - Innovations in Oncology Corporate Access Day Recap

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 59

11/10/2016

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 60

11/10/2016

Company Report

Pages: 7

3Q16 Results; Busy Times at the Company as We Await Catalysts

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party